Abstract

Cervical cancer remains a significant global health challenge, particularly in low-resource settings where access to preventive measures and treatment options is limited. While traditional therapies such as surgery, chemotherapy, and radiotherapy have been effective, they often come with significant side effects and limitations in advanced or recurrent cases. The integration of targeted molecular therapies and immunotherapy represents a promising frontier in cervical cancer treatment, offering precision, reduced toxicity, and improved outcomes. This article explores the methodologies, results, and implications of these innovative approaches, highlighting their transformative potential in the fight against cervical cancer.